|  | Cancer | Lymphoma

Lymphoma Mortality: Direct Organ Involvement and Complication‑Driven Death

Lymphoma (Hodgkin and non‑Hodgkin) causes death through two primary pathways:

1. Direct Vital Organ Compromise

  • Respiratory failure: Mediastinal/hilar nodal masses compress airways (trachea, bronchi) → atelectasis, post‑obstructive pneumonia, respiratory arrest.
  • Cardiac tamponade/failure: Pericardial effusion from nodal infiltration or direct myocardial invasion → obstructive shock.
  • Superior vena cava (SVC) syndrome: SVC obstruction → cerebral edema, airway compromise.
  • Hepatic failure: Massive hepatic infiltration or Budd‑Chiari syndrome (hepatic vein thrombosis).
  • Renal failure: Ureteral obstruction by retroperitoneal nodes → hydronephrosis.
  • CNS involvement: Primary CNS lymphoma or leptomeningeal spread → increased ICP, seizures.

2. Treatment‑Related and Disease‑Related Complications

  • Infection (leading cause of death in remission): Neutropenia from chemo, hypogammaglobulinemia, T‑cell depletion → sepsis, pneumonia, fungal, viral (CMV, HSV, VZV, PJP).
  • Bleeding: Thrombocytopenia (marrow infiltration, chemo) → intracranial hemorrhage, GI bleed.
  • Cancer cachexia: Cytokine‑driven catabolism → weight loss, sarcopenia, anorexia, organ failure.
  • Secondary malignancies: Therapy‑related MDS/AML, solid tumors (radiation fields).
  • Cardiotoxicity: Anthracycline cardiomyopathy, radiation pericarditis/CAD.
  • Venous thromboembolism: Hypercoagulable state + central lines + immobility.

Prognostic Context

  • Aggressive NHL (DLBCL, Burkitt) — rapid organ compromise if untreated.
  • Indolent NHL (follicular) — transformation, infection over years.
  • Hodgkin lymphoma — high cure rate; late deaths from secondary cancers, cardiac disease.

Modern risk‑adapted therapy and supportive care (growth factors, IVIG, antimicrobial prophylaxis) have shifted mortality toward late effects and comorbidities.

Lymphoma - Related Articles